Investigating the combined effects of jadomycin B and celecoxib against triple-negative breast cancer using zebrafish larval xenografts

Breast cancer affects 1 in 8 Canadian women over their lifetime. Triple-negative breast cancer (TNBC) represents 10-20 % of all advanced stage breast cancers, often developing multi-drug resistance (MDR), commonly resulting in treatment failure. Jadomycin B (JB), a natural product of Streptomyces venezuelae, maintains cytotoxicity against MDR TNBCs, shown to be enhanced when combined with selective COX-2 inhibitor, celecoxib (CXB). Our objectives were to generate a fluorescent human TNBC cell line, as well as evaluate the toxicity and anticancer effect of JB combined with CXB using zebrafish larval xenografts. Fluorescent human TNBC MDA-MB-231 cells (231-EGFP) were generated and characterized for zebrafish larval xenografts. A maximum tolerated dose (MTD) in zebrafish larvae was determined for JB (20 mM) and CXB (5 mM). Zebrafish embryos were xenotransplanted with 231-EGFP cells and treated with the MTD of JB CXB. The combination of JB and CXB resulted in a 75% reduction in 231-EGFP flu..., , # Data from: Investigating the combined effects of jadomycin B and celecoxib against triple-negative breast cancer using zebrafish larval xenografts

Hailey M. Stack, Michael G. Morash, Brendan T. McKeown, Lee D. Ellis, Kerry B. Goralski

Contact of Authors: 

Hailey M. Stack

Department of Pharmacology, Faculty of Medicine, Dalhousie University

Halifax, NS, B3H 4R2

[[e-mail]](mailto:[e-mail])

<br />

Kerry B. Goralski

College of Pharmacy, Faculty of Health, Department of Pharmacology

Halifax, NS B3H 4R2

[[e-mail]](mailto:[e-mail])

<br />

Dataset DOI: [10.5061/dryad.3bk3j9kxp](https://doi.org/10.5061/dryad.3bk3j9kxp)

## Description of the data and file structure

raw_toxicity_data: excel file containing raw data collected from a phenotypic (fish embryo toxicity assay/FET) and a behavioural assay of various treatment groups (jadomycin B: 2.5-80 uM; celecoxib: 2.5-25 uM; combination treatment: jadomycin B (5-20 uM) + celecoxib (5-10...,

乳腺癌在加拿大女性中的终身发病率高达八分之一。三阴性乳腺癌（Triple-negative breast cancer, TNBC）占所有晚期乳腺癌的10%~20%，常产生多药耐药性（multi-drug resistance, MDR），往往导致治疗失败。Jadomycin B（JB）是委内瑞拉链霉菌（Streptomyces venezuelae）的天然产物，对多药耐药性三阴性乳腺癌仍具有细胞毒性；当其与选择性环氧合酶-2（cyclooxygenase-2, COX-2）抑制剂塞来昔布（celecoxib, CXB）联合使用时，细胞毒性可显著增强。本研究旨在构建荧光标记的人三阴性乳腺癌细胞系，并利用斑马鱼幼虫异种移植模型评估JB联合CXB的毒性与抗癌效果。

我们成功构建并鉴定了适用于斑马鱼幼虫异种移植的荧光标记人三阴性乳腺癌MDA-MB-231细胞系（231-EGFP）。测定了JB（20 mM）与CXB（5 mM）在斑马鱼幼虫中的最大耐受剂量（maximum tolerated dose, MTD）。将231-EGFP细胞异种移植至斑马鱼胚胎后，采用上述最大耐受剂量进行给药处理。JB与CXB联合给药可使231-EGFP的荧光信号降低75%……

数据来源：《利用斑马鱼幼虫异种移植模型研究jadomycin B与塞来昔布联合抗三阴性乳腺癌的效果》
作者：Hailey M. Stack、Michael G. Morash、Brendan T. McKeown、Lee D. Ellis、Kerry B. Goralski

通讯作者：
Hailey M. Stack
达尔豪西大学（Dalhousie University）医学院药理学系
哈利法克斯，新斯科舍省，B3H 4R2
邮箱：[e-mail]

Kerry B. Goralski
健康学院药学院、药理学系
哈利法克斯，新斯科舍省 B3H 4R2
邮箱：[e-mail]

数据集DOI：[10.5061/dryad.3bk3j9kxp](https://doi.org/10.5061/dryad.3bk3j9kxp)

## 数据与文件结构说明
raw_toxicity_data：Excel格式文件，收录了不同给药组（jadomycin B：2.5~80 μM；塞来昔布：2.5~25 μM；联合给药组：jadomycin B（5~20 μM）+塞来昔布（5~10 μM）……）的鱼胚胎毒性实验（fish embryo toxicity assay, FET）与行为学实验的原始采集数据。